GRTX · As filed with the SEC
Galera Therapeutics balance sheet, by quarter
The statement as Galera Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED BALANCE SHEETS (unaudited) · USD
| USD | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | 5,500,000 | 6,375,000 | 4,473,000 | 5,230,000 | 6,686,000 | 8,289,000 | 8,455,000 | 10,749,000 |
| Subscription receivable | — | 0 | 0 | 0 | 0 | 635,000 | — | — |
| Prepaid expenses and other current assets | 563,000 | 720,000 | 428,000 | 717,000 | 874,000 | 1,077,000 | 444,000 | 1,213,000 |
| Total current assets | 6,063,000 | 7,095,000 | 4,901,000 | 5,947,000 | 7,560,000 | 10,001,000 | 8,899,000 | 11,962,000 |
| Property and equipment, net | — | — | — | — | — | 0 | 0 | 56,000 |
| Acquired intangible asset | — | — | — | — | — | 0 | 0 | 2,258,000 |
| Goodwill | — | — | — | — | — | 0 | 0 | 881,000 |
| Right-of-use lease assets | — | — | — | — | — | 0 | 0 | 1,136,000 |
| Other assets | 101,000 | 101,000 | 101,000 | 101,000 | 101,000 | 100,000 | 2,000 | 90,000 |
| Total assets | 6,164,000 | 7,196,000 | 5,002,000 | 6,048,000 | 7,661,000 | 10,101,000 | 8,901,000 | 16,383,000 |
| Liabilities, redeemable convertible preferred stock and stockholders' deficit | ||||||||
| Current liabilities: | ||||||||
| Liabilities, Current | — | 645,000 | 598,000 | 347,000 | 975,000 | 1,666,000 | 914,000 | 2,126,000 |
| Royalty purchase liability | — | 0 | 151,049,000 | 151,049,000 | 151,049,000 | 151,049,000 | 151,049,000 | 151,049,000 |
| Lease liabilities, net of current portion | — | — | — | — | — | 0 | 0 | 1,037,000 |
| Warrant liability | — | 0 | 0 | 0 | 0 | 1,055,000 | — | — |
| Deferred tax liability | — | — | — | — | — | 0 | 0 | 203,000 |
| Accounts payable | 699,000 | 265,000 | 434,000 | 202,000 | 744,000 | 1,275,000 | 296,000 | 812,000 |
| Accrued expenses | 442,000 | 380,000 | 164,000 | 145,000 | 231,000 | 391,000 | 618,000 | 1,157,000 |
| Lease liabilities | — | — | — | — | — | 0 | 0 | 157,000 |
| Liabilities | 1,141,000 | 645,000 | 151,647,000 | 151,396,000 | 152,024,000 | 153,770,000 | 151,963,000 | 154,415,000 |
| Stockholders' deficit: | ||||||||
| Series B redeemable convertible preferred stock, $0.001 par value: 10,000,000 shares authorized; 119,318 shares issued and outstanding at March 31, 2026 and December 31, 2025 | — | — | — | — | — | — | 0 | 0 |
| Series B Redeemable Convertible Preferred Stock | 4,295,000 | 2,577,000 | 2,577,000 | 2,597,000 | 2,864,000 | 4,372,000 | — | — |
| Common stock, $0.001 par value: 200,000,000 shares authorized; 75,462,390 shares issued and outstanding at March 31, 2026 and December 31, 2025 | 75,000 | 75,000 | 75,000 | 75,000 | 75,000 | 75,000 | 54,000 | 54,000 |
| Additional paid-in capital | 309,573,000 | 311,213,000 | 311,121,000 | 311,010,000 | 310,653,000 | 308,247,000 | 308,316,000 | 307,765,000 |
| Accumulated deficit | (308,920,000) | (307,314,000) | (460,418,000) | (459,030,000) | (457,955,000) | (456,363,000) | (451,432,000) | (445,851,000) |
| Total stockholders' deficit | 728,000 | 3,974,000 | (149,222,000) | (147,945,000) | (147,227,000) | (148,041,000) | (143,062,000) | (138,032,000) |
| Total liabilities, redeemable convertible preferred stock and stockholders` equity | 6,164,000 | 7,196,000 | 5,002,000 | 6,048,000 | 7,661,000 | 10,101,000 | 8,901,000 | 16,383,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.